Laura Powell, Author at EverGlade

Laura Powell

Laura Powell, Director

Four Takeaways from the 2026 RRPV General Membership Meeting

Leave a Comment / All Posts, BARDA, Industry News, Life Sciences / By

The Rapid Response Partnership Vehicle (RRPV) consortium, through the Biomedical Advanced Research and Development Authority (BARDA), convenes government, industry, academic, nonprofit, and service-provider organizations working to accelerate medical countermeasures for emerging infectious diseases and other national preparedness priorities. EverGlade team members Laura Powell, PhD, PMP, and Richard Merlino, MBA attended last week’s General Membership Meeting

Four Takeaways from the 2026 RRPV General Membership Meeting Read More »

ARPA-H THRIVE ISO Amendment 1

Leave a Comment / ARPA-H, Life Sciences / By

THRIVE+ISO_Amendment_No_1_Tracked_Changes (1) Amendment released for ARPA-H’s THRIVE Initiative The Advanced Research Projects Agency for Health (ARPA-H), through its Health Science Futures Office, released Amendment No. 1 for the Treating Hereditary Rare diseases with In Vivo precision genetic mEdicines (THRIVE) Innovative Solutions Opening (ISO) (ARPA-H-SOL-25-122) on October 17, 2025. The updates focus on changes to the

ARPA-H THRIVE ISO Amendment 1 Read More »

woman in lab coat developing new technologies

DTRA Funding Novel Technologies and Medical Countermeasures

Leave a Comment / All Posts / By

Amendment to BAA Outlines New DTRA Funding Opportunities to Develop Novel Technologies and Medical Countermeasures Against Weapons of Mass Destruction (WMD) and Emerging Threats The Defense Threat Reduction Agency (DTRA) recently published an amendment to their Broad Agency Announcement (‘BAA”) No. HDTRA1-22-S-0003, which provides additional funding opportunities to identify and counter Weapons of Mass Destruction

DTRA Funding Novel Technologies and Medical Countermeasures Read More »

Scroll to Top